Evidence map›Paper›PMID 38749730›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Magnetic Resonance Imaging/cerebrospinal Fluid-negative Myelitis Following COVID-19 with a Dramatic Response to Early Aggressive Immunosuppressive Therapy.

Motohiro Okumura, Takeo Sato, Marina Masui, Tatsushi Kokubu, Tadashi Umehara, Tomoko Okamoto, Yasuyuki Iguchi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Motohiro OkumuraDepartment of Neurology, The Jikei University School of Medicine, Japan.
Takeo SatoDepartment of Neurology, The Jikei University School of Medicine, Japan.
Marina MasuiDepartment of Neurology, The Jikei University School of Medicine, Japan.
Tatsushi KokubuDepartment of Neurology, The Jikei University School of Medicine, Japan.
Tadashi UmeharaDepartment of Neurology, The Jikei University School of Medicine, Japan.
Tomoko OkamotoDepartment of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan.
Yasuyuki IguchiDepartment of Neurology, The Jikei University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 57-year-old man presented with subacute-onset paraparesis, bilateral dysesthesia in his lower extremities, and bladder/bowel disturbance six weeks after being infected with severe acute respiratory syndrome coronavirus 2 infection [coronavirus disease 2019 (COVID-19)]. A neurological examination suggested transverse myelitis at the level of the lower thoracic spinal cord. However, repeated spinal magnetic resonance imaging (MRI) showed no abnormalities in the spinal cord. Laboratory and cerebrospinal fluid (CSF) tests ruled out other etiologies of myelitis, eventually suggesting COVID-19-associated myelitis. Aggressive immunosuppressive therapy, started soon after hospitalization, dramatically improved his symptoms. Early aggressive immunosuppressive therapy should therefore be considered in cases of MRI/CSF-negative myelitis associated with COVID-19.

Indexed as

COVID-19Immunosuppressive AgentsMagnetic Resonance ImagingHumansMaleMiddle AgedMyelitisMyelitis, TransverseSARS-CoV-2Spinal CordTreatment OutcomeImmunosuppressive AgentsCOVID-19immunosuppressive therapyMRI/CSF-negativemyelitisSARS-CoV-2

Identifiers

PMID38749730
PMCPMC11358746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.